Tradestie Institutional Equity Comparison Engine

INKT vs MUSE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

INKT Overall Edge

INKT Captures Institutional Edge (1โ€“1 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MiNK Therapeutics, Inc. Common Stock (INKT) driven by superior Growth & Margin while MUSE counters with relative strength in Momentum & Technical. Fundamentally, INKT trades at N/M Forward P/E with -5720.7% operating margin (+0.0% YoY revenue) versus MUSE at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, INKT sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against MUSE sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
INKT N/M vs MUSE N/M Fwd P/E
Growth & Margin Winner INKT
Op Margin -5720.7% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner MUSE
1Y -27.2% vs -6.0% ยท 52W Pos 3% vs 0%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
INKT NASDAQ
MiNK Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$8.02
-6.85% 1D
Market Cap $44.2M
1M Return -20.28%
1Y Return -27.22%
Forward P/E N/M
Unified AI Score
42.8 / 100 HOLD
Tech 33.0 Fund 45.0 Flow 50.0 Mom 60.0
MUSE US Equity
MUSE
Institutional Equity
$47.67
-0.13% 1D
Market Cap N/A
1M Return -0.65%
1Y Return -6.03%
Forward P/E N/M
Unified AI Score
45.9 / 100 HOLD
Tech 48.0 Fund 50.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: INKT -27.22% MUSE -6.03% Spread: +21.9 pp (MUSE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
INKT TTM Op. Margin: -5720.7% MUSE TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on INKT vs MUSE. Trailing 12-month operating profitability (INKT -5720.7% vs MUSE N/A) and valuation multiples (INKT N/M vs MUSE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: INKT (6) vs MUSE (2)
Institutional Metric INKT MUSE Criterion Row Winner
Market Capitalization Scale $44.2M N/A Larger Scale INKT
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% N/A Higher Growth INKT
Operating Margin (TTM) Profitability -5720.7% N/A Higher Margin INKT
Net Profit Margin Profitability 0.0% N/A Higher Margin INKT
Return on Equity (ROE) Capital Efficiency -1239.0% N/A Higher ROE INKT
52-Week Range Position Momentum 3% ($8โ€“$17) 0% ($48โ€“$52) Stronger Trend INKT
Beta / 30D Volatility Risk Regime 0.59ฮฒ ยท 55% Vol 0.10ฮฒ ยท 4% Vol Lower Realized Risk MUSE
Unified Institutional Score Composite Signal 42.8 / 100 (HOLD) 45.9 / 100 (HOLD) Higher Composite MUSE

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full INKT vs MUSE Buy Guide
INKT UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live INKT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MUSE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MUSE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither INKT nor MUSE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.